Валеология: Здоровье, Болезнь, Выздоровление. 2020; : 155-158
АГРЕССИВНЫЕ ФОРМЫ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
Аннотация
Рак предстательной железы является наиболее распространенным раком у мужчин во всем мире, по оценкам – 1 600 000 случаев заболеваемости и 366 000 случаев смертности ежегодно.
Даже в странах с достаточно развитыми методами диагностики и лечения, таких как Франция и Германия, показатель заболеваемости по изучению периода с 2005 года составляет от 100–130 на 100 000 каждый год.
Необходимость в разработке новых методов диагностики и лечения растет. Вероятно, использование геномных инструментов может снизить показатели заболеваемости, смертности и улучшить качество жизни пациентов с РПЖ. В связи с низкой специфичностью ПСА, есть необходимость модернизировать метод скрининга, используя современные методы изучения кандидатных генов.
Список литературы
1. Torre L. A., Bray F., Siegel R. L., et all // ACA Cancer// J Clin. 2015 Mar; 65 (2) : 87-108.
2. Binder-Foucard F., Bossard N., Delafosse P., et all // Cancer incidence and mortality in France over the 1980-2012 period: solid tumors.// Rev EpidemiolSantePublique. 2014; 62 (2) : 95–108.
3. Crocetti E., De Angelis R., Buzzoni C., at all // Cancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability // Br J Cancer. 2013; 109 (1) : 219–228.
4. Bray F., Lortet-Tieulent J., Ferlay J., Forman D., Auvinen A. // Prostate cancer incidence and mortality trends in 37 European countries: an overview // Eur J Cancer. 2010; 46 (17) : 3040–3052.
5. J. Smith-Palmer, C. Takizawa, W. Valentine // Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada // BMC Urol. 2019; 19 : 19.
6. Cancer Research UK. Prostate cancer incidence statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Eight. Accessed 16 June 2016.
7. Bell K. J., Del Mar C., Wright G., Dickinson J., Glasziou P. //
8. Prevalence of incidental prostate cancer: A systematic review of autopsy studies // Int J Cancer. 2015 Oct 1; 137 (7) : 1749-57
9. Disease Ontologyrelease 2019-05-13 — 2019-05-13 — 2019.
10. Mistry M., Parkin D. M., Ahmad A. S., Sasieni P. // Cancer incidence in the United Kingdom: projections to the year 2030 // Br J Cancer. 2011; 105 (11) : 1795–1803
11. Hall P. S., Hamilton P., Hulme C. T., Meads D. M., Jones H., Newsham A., Marti J., Smith A. Fet all // 11. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data // Br J Cancer. 2015; 112 (5) : 948–956.
12. Sullivan P. W., Mulani P. M., Fishman M., Sleep D. // Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer // Qual Life Res. 2007 May; 16 (4) : 571-5.
13. Bremner K. E., Tomlinson G., Krahn M. D. // Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients // Qual Life Res. 2007 Dec; 16 (10) : 1665-75.
14. Feletto E., Bang A., Cole-Clark D., Chalasani V., Rasiah K., Smith D. P. An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015; 33 (11) : 1677–1687.
15. Menegatou E., Claeys C., Wasserman D., Tomaszewski K. // Assessment of Health States and Erectile Dysfunction-Associated Quality of Life Among Adult Males and Females With Male Partners in Germany, the United Kingdom and the United States // Value Health. 2014 Nov; 17 (7) : A516.
16. Bray F., Lortet-Tieulent J., Ferlay J., et all // Prostate cancer incidence and mortality trends in 37 European countries: an overview // Eur J Cancer. 2010; 46 (17) : 3040–3052.
17. Esfahani M., Ataei N., Panjehpour M. // Biomarkers for evaluation of prostate cancer prognosis // Asian Pac J Cancer Prev. 2015; 16 (7) : 2601-11.
18. Dörr M., Hölzel D., Schubert-Fritschle G., Engel J. et all // Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years // Oncol Res Treat. 2015; 38 (1–2) : 8–14.
19. Greenberg D. C., Wright K. A., Lophathanon A., Muir K. R., Gnanapragasam V. J. Changing presentation of prostate cancer in a UK population--10 year trends in prostate cancer risk profiles in the East of England. Br J Cancer. 2013; 109 (8) : 2115–2120.
20. Marcos-Gragera R., Salmerón D., Izarzugaza I., et all // Trends in prostate cancer survival in Spain: results from population-based cancer registries // Clin Trans l Oncol. 2012 Jun; 14 (6) : 458-64.
21. Seikkula H. A., Kaipia A. J., Rantanen M. E., et all // Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA // Acta Oncol. 2017 Jul; 56 (7) : 971-977].
Valeology: Health - Illnes - recovery. 2020; : 155-158
AGGRESSIVE PROSTATIC CANCER FORMS
Abstract
Prostate cancer is the most common cancer in men worldwide, with an estimated 1,600,000 cases of morbidity and 366,000 deaths annually.
Even in countries with well-developed methods of diagnosis and treatment, such as France and Germany, the incidence rate for the study of the period from 2005 is from 100-130 per 100,000 every year.
The need to develop new methods of diagnosis and treatment is growing. It is likely that the use of genomic tools can reduce morbidity, mortality and improve the quality of life of patients with prostate cancer. Due to the low specificity of PSA, there is a need to modernize the screening method using modern methods for studying candidate genes.
References
1. Torre L. A., Bray F., Siegel R. L., et all // ACA Cancer// J Clin. 2015 Mar; 65 (2) : 87-108.
2. Binder-Foucard F., Bossard N., Delafosse P., et all // Cancer incidence and mortality in France over the 1980-2012 period: solid tumors.// Rev EpidemiolSantePublique. 2014; 62 (2) : 95–108.
3. Crocetti E., De Angelis R., Buzzoni C., at all // Cancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability // Br J Cancer. 2013; 109 (1) : 219–228.
4. Bray F., Lortet-Tieulent J., Ferlay J., Forman D., Auvinen A. // Prostate cancer incidence and mortality trends in 37 European countries: an overview // Eur J Cancer. 2010; 46 (17) : 3040–3052.
5. J. Smith-Palmer, C. Takizawa, W. Valentine // Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada // BMC Urol. 2019; 19 : 19.
6. Cancer Research UK. Prostate cancer incidence statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Eight. Accessed 16 June 2016.
7. Bell K. J., Del Mar C., Wright G., Dickinson J., Glasziou P. //
8. Prevalence of incidental prostate cancer: A systematic review of autopsy studies // Int J Cancer. 2015 Oct 1; 137 (7) : 1749-57
9. Disease Ontologyrelease 2019-05-13 — 2019-05-13 — 2019.
10. Mistry M., Parkin D. M., Ahmad A. S., Sasieni P. // Cancer incidence in the United Kingdom: projections to the year 2030 // Br J Cancer. 2011; 105 (11) : 1795–1803
11. Hall P. S., Hamilton P., Hulme C. T., Meads D. M., Jones H., Newsham A., Marti J., Smith A. Fet all // 11. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data // Br J Cancer. 2015; 112 (5) : 948–956.
12. Sullivan P. W., Mulani P. M., Fishman M., Sleep D. // Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer // Qual Life Res. 2007 May; 16 (4) : 571-5.
13. Bremner K. E., Tomlinson G., Krahn M. D. // Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients // Qual Life Res. 2007 Dec; 16 (10) : 1665-75.
14. Feletto E., Bang A., Cole-Clark D., Chalasani V., Rasiah K., Smith D. P. An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015; 33 (11) : 1677–1687.
15. Menegatou E., Claeys C., Wasserman D., Tomaszewski K. // Assessment of Health States and Erectile Dysfunction-Associated Quality of Life Among Adult Males and Females With Male Partners in Germany, the United Kingdom and the United States // Value Health. 2014 Nov; 17 (7) : A516.
16. Bray F., Lortet-Tieulent J., Ferlay J., et all // Prostate cancer incidence and mortality trends in 37 European countries: an overview // Eur J Cancer. 2010; 46 (17) : 3040–3052.
17. Esfahani M., Ataei N., Panjehpour M. // Biomarkers for evaluation of prostate cancer prognosis // Asian Pac J Cancer Prev. 2015; 16 (7) : 2601-11.
18. Dörr M., Hölzel D., Schubert-Fritschle G., Engel J. et all // Changes in prognostic and therapeutic parameters in prostate cancer from an epidemiological view over 20 years // Oncol Res Treat. 2015; 38 (1–2) : 8–14.
19. Greenberg D. C., Wright K. A., Lophathanon A., Muir K. R., Gnanapragasam V. J. Changing presentation of prostate cancer in a UK population--10 year trends in prostate cancer risk profiles in the East of England. Br J Cancer. 2013; 109 (8) : 2115–2120.
20. Marcos-Gragera R., Salmerón D., Izarzugaza I., et all // Trends in prostate cancer survival in Spain: results from population-based cancer registries // Clin Trans l Oncol. 2012 Jun; 14 (6) : 458-64.
21. Seikkula H. A., Kaipia A. J., Rantanen M. E., et all // Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA // Acta Oncol. 2017 Jul; 56 (7) : 971-977].
